Preview

Regulatory Research and Medicine Evaluation

Advanced search

Pitfalls of patenting and state authorization of medicines

Abstract

During the lifecycle of a medicine - from its development to consumption - the developer has to go through several stages, such as obtaining the exclusive right for a medicine, obtaining permission to produce the medicine, obtaining permission to distribute and use the medicine, i.e. the developer has to patent and register the invention and obtain a marketing authorization for it. In order to accomplish these procedures that fall within the remit of the Federal Service for Intellectual Property and the Ministry of Health of Russia, developers have to submit documents described in relevant legislative acts. The article describes the patenting procedure used by the Federal Service for Intellectual Property, including examination as to form and substantive examination. It also addresses some problems associated with patenting medicines and their state authorization. A conclusion is drawn on the importance of searching for unexpired patents and their analysis in order to prevent situations in which developers of medicines infringe the rights of others.

About the Authors

V. I. Semenov
Federal State Budgetary Institution «Federal Institution of Industrial Property» of Federal Service for Intellectual Property
Russian Federation


E. B. Gavrilova
Federal State Budgetary Institution «Federal Institution of Industrial Property» of Federal Service for Intellectual Property
Russian Federation


N. B. Lyskov
Federal State Budgetary Institution «Federal Institution of Industrial Property» of Federal Service for Intellectual Property
Russian Federation


References

1. On Circulation of Medicines. Federal Law, April 12, 2010 № 61-FZ (in Russian).

2. The Civil Code of the Russian Federation. M.: Prospekt; 2015 (in Russian).


Review

For citations:


Semenov V.I., Gavrilova E.B., Lyskov N.B. Pitfalls of patenting and state authorization of medicines. The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. 2015;(4):43-46. (In Russ.)

Views: 756


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 3034-3062 (Print)
ISSN 3034-3453 (Online)